Collectively, these results suggest that KIFC2 is highly amplified in HR+/HER2– BC and that its expression promotes growth and resistance to ET and CDK4/6 inhibitors in HR+/HER2– BC by USP9X-mediated stabilization of CDK4 (Figure 7M). This evidence concerns the gene ERBB2 and breast cancer.